Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers

NCT ID: NCT04568772

Last Updated: 2021-09-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-25
• Study Completion Date: 2021-08-03

Brief Summary

The aim of this study is to evaluate the influence of tegoprazan on the pharmacokinetics of proguanil in healthy volunteers.

Detailed Description

Evaluation criteria

• Pharmacokinetic assessment with plasma concentrations of proguanil and cycloguanil
• Safety assessments with adverse event monitoring including subjective/objective symptoms, physical examination, vital signs, electrocardiogram, and laboratory tests

Conditions

Gastroesophageal Reflux Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Atovaquone/Proguanil 250/100 mg

A single oral administration of atovaquone/proguanil 250/100 mg

Group Type: ACTIVE_COMPARATOR

Atovaquone / Proguanil 250/100 mg

Intervention Type: DRUG

Atovaquone / Proguanil 250/100 mg tablet

Tegoprazan 50 mg + Atovaquone/Proguanil 250/100 mg

Oral administration of tegoprazan 50 mg once daily for 6 days and then co-administration of tegoprazan 50 mg and atovaquone/proguanil 250/100 mg at 7 day

Group Type: EXPERIMENTAL

Atovaquone / Proguanil 250/100 mg

Intervention Type: DRUG

Atovaquone / Proguanil 250/100 mg tablet

Tegoprazan 50 mg

Intervention Type: DRUG

Tegoprazan 50 mg tablet

Esomeprazole 40 mg + Atovaquone/Proguanil 250/100 mg

Oral administration of esomeprazole 40 mg once daily for 6 days and then co-administration of esomeprazole 40 mg and atovaquone/proguanil 250/100 mg at 7 day

Group Type: EXPERIMENTAL

Atovaquone / Proguanil 250/100 mg

Intervention Type: DRUG

Atovaquone / Proguanil 250/100 mg tablet

Esomeprazole 40 mg

Intervention Type: DRUG

Esomeprazole 40 mg tablet

Vonoprazan 20 mg + Atovaquone/Proguanil 250/100 mg

Oral administration of vonoprazan 20 mg once daily for 6 days and then co-administration of vonoprazan 20 mg and atovaquone/proguanil 250/100 mg at 7 day

Group Type: EXPERIMENTAL

Atovaquone / Proguanil 250/100 mg

Intervention Type: DRUG

Atovaquone / Proguanil 250/100 mg tablet

Vonoprazan 20 mg

Intervention Type: DRUG

Vonoprazan 20 mg tablet

Interventions

Atovaquone / Proguanil 250/100 mg

Atovaquone / Proguanil 250/100 mg tablet

Intervention Type: DRUG

Tegoprazan 50 mg

Tegoprazan 50 mg tablet

Intervention Type: DRUG

Esomeprazole 40 mg

Esomeprazole 40 mg tablet

Intervention Type: DRUG

Vonoprazan 20 mg

Vonoprazan 20 mg tablet

Intervention Type: DRUG

Other Intervention Names

Malarone; K-cab; Nexium; Takecab

Eligibility Criteria

Inclusion Criteria

• Healthy adult aged ≥ 19 years and ≤ 50 years at the time of screening
• Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with body mass index (BMI) of ≥ 19.0 kg/m2 and ≤ 30.0 kg/m2 at the time of screening
• Extensive metabolizer (*1/*1) by CYP2C19 genotyping
• A subject without any congenital or chronic disease, and has no medical examination result as pathological symptoms or signs
• A subject who listened to sufficient explanation and fully understood this study, and voluntarily decided to participate and agreed in writing to comply with the precautions
• A subject determined eligible for this study by investigator based physical examination, clinical laboratory tests, interview, etc.

Exclusion Criteria

• A subject with clinically significant hepatobiliary (severe hepatic impairment, etc.), renal (severe renal impairment, etc.), neurologic, immunologic, respiratory, gastrointestinal, endocrine, blood•oncology, cardiovascular (heart failure, Torsades de pointes, etc.), urinary, or, psychical diseases (except for simple dental past history such as tartar, impacted tooth, or wisdom tooth) or a history
• A subject who has hypersensitivity to the investigational products, drugs containing the same class, or other drugs (penicillin and antibiotics, etc.), or a history of clinically significant hypersensitivity
• A subject with a history of gastrointestinal disorders (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux disease, Crohn's disease, etc.) or surgery (except for simple appendectomy and herniotomy) that may affect the safety and pharmacokinetics of the investigational products
• A subject with the following results in the screening test:
• Blood AST (GOT), ALT (GPT): > Normal range upper × 1.5
• Creatinine clearance calculated by MDRD equation: < 80mL/min
• QTc interval: > 450 ms
• Fasting serum glucose: > 126 mg/dL
• Positive serological test (syphilis test, hepatitis B test, hepatitis C test, human immunodeficiency virus (HIV) test)
• A subject with systolic blood pressure < 90 mmHg or > 150 mmHg, or diastolic blood pressure < 50 mmHg or > 100 mmHg when vital signs are measured in sitting position after resting for at least 3 minutes
• A subject with a history of or positive urine screening for drug abuse
• A subject who administered any prescription drugs or herbal medicine within 2 weeks prior to the expected date of the first dose, or any over-the-counter drug (OTC drug, health functional food or vitamin within 1 week prior to the expected date of the first dose (However, can participate in the study if otherwise decided eligible by the investigator), or is expected to administer it
• A subject who administered drugs that induce or inhibit the drug metabolizing enzymes, such as barbitals, within 1 week prior to the expected date of the first dose
• A subject who participated in other clinical trial or bioequivalence study within 6 months prior to the expected date of the first dose
• A subject who donated whole blood within 2 months or the component blood within 1 month prior to the expected date of the first dose, or received blood transfusion within 1 month prior to the expected date of the first dose
• A subject with persistent alcohol intake (> 21 units/week, 1 unit = 10 g of pure alcohol), or inability to abstain from drinking from 3 days before the expected date of the first dose until the last discharge
• A subject who is a currently smoker (But, can be eligible if he or she quitted smoking 3 months ago), or is not able to cease smoking from 3 months before the expected date of the first dose until the last discharge
• A subject with inability to refrain from grapefruit-containing food from 3 days before the expected date of the first dose until the last discharge
• A subject with excessive caffeine intake (> 5 units/day), or inability to refrain from caffeine or caffeine-containing food from 3 days before the expected date of the first dose until the last discharge
• A subject with inability to use a medically acceptable double contraception or contraception throughout the study and for at least 4 weeks after the last dose, and with inability to agree to donate sperm until the period

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Seoul National University Hospital

OTHER

Sponsor Role: lead

Responsible Party

SeungHwan Lee

Clinical Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

SeungHwan Lee, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Seoul National University Hospital

Locations

Seoul National University Hospital, Clinical Trial Center

Seoul, , South Korea

Countries

South Korea

References

Yang E, Ji SC, Jang IJ, Lee S. Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole. Clin Pharmacokinet. 2023 Apr;62(4):599-608. doi: 10.1007/s40262-023-01228-4. Epub 2023 Mar 10.

Reference Type: DERIVED

PMID: 36897544 (View on PubMed)

Other Identifiers

Tegoprazan_CYP2C19_DDI

Identifier Type: -

Identifier Source: org_study_id